Evidence map›Paper›PMID 33255900›Full record

ArticleAntibiotics (Basel, Switzerland)2020

Fatty Acid Conjugation Leads to Length-Dependent Antimicrobial Activity of a Synthetic Antibacterial Peptide (Pep19-4LF).

Philip Storck, Florian Umstätter, Sabrina Wohlfart, Cornelius Domhan, Christian Kleist, Julia Werner, Klaus Brandenburg, Stefan Zimmermann, Uwe Haberkorn, Walter Mier and 1 more

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Mini reviews in medicinal chemistry · 2025
    Review
  5. Article
  6. Antibiotics (Basel, Switzerland) · 2022
    Article
  7. Article
  8. Effects of LysineAntibiotics (Basel, Switzerland) · 2022
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Philip StorckDepartment of Nuclear Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Florian UmstätterDepartment of Nuclear Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Sabrina WohlfartDepartment of Nuclear Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Cornelius DomhanInstitute of Pharmacy and Molecular Biotechnology, Ruprecht-Karls-University, 69120 Heidelberg, Germany.
Christian KleistDepartment of Nuclear Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Julia WernerDepartment of Nuclear Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Klaus BrandenburgBrandenburg Antiinfektiva GmbH, Parkallee 10b, 23845 Borstel, Germany.
Stefan ZimmermannDepartment of Infectious Diseases, Medical Microbiology and Hygiene, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Uwe HaberkornDepartment of Nuclear Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Walter MierDepartment of Nuclear Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Philipp UhlDepartment of Nuclear Medicine, Heidelberg University Hospital, 69120 Heidelberg, Germany.ORCID 0000-0002-8616-5599
Heidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increasing number of infections caused by multidrug-resistant bacteria requires an intensified search for new antibiotics. Pep19-4LF is a synthetic antimicrobial peptide (GKKYRRFRWKFKGKLFLFG) that was previously designed with the main focus on high antimicrobial activity. The hydrophobic motif, LFLFG, was found to be essential for antimicrobial activity. However, this motif shows several limitations such as aggregation in biological media, low solubility, and small yields in peptide synthesis. In order to obtain more appropriate peptide characteristics, the hydrophobic motif was replaced with fatty acids. For this purpose, a shortened variant of Pep19-4LF (Pep19-short; GKKYRRFRWKFKGK) was synthesized and covalently linked to saturated fatty acids of different chain lengths. The peptide conjugates were tested with respect to their antibacterial activity by microdilution experiments on different bacterial strains. The length of the fatty acid was found to be directly correlated to the antimicrobial activity up to an ideal chain length (undecanoic acid, C11:0). This conjugate showed high antimicrobial activity in absence of toxicity. Time-kill studies revealed a fast and bactericidal mode of action. Furthermore, the first in vivo experiments of the conjugate in rodents demonstrated pharmacokinetics appropriate for application as a drug. These results clearly indicate that the hydrophobic motif of the peptide can be replaced by a single fatty acid of medium length, simplifying the design of this antimicrobial peptide while retaining high antimicrobial activity in the absence of toxicity.

Indexed as

antimicrobial activityEnterococcus faeciumfatty acid conjugationStaphylococcus aureussynthetic antimicrobial peptides

Identifiers

PMID33255900
PMCPMC7760514
OpenAlexW3107575408

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.